Free press releases distribution network?

Agency / Source: Bio3 Research Srl

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Bio3 Research Granted by the Australian PO a Patent in the Field of HMGB1 - Italy, has been granted by the Australian Patent Office a patent in the field of cardiovascular diseases related to HMGB1 over-expression and for the use of HMGB1 protein in connective tissue regeneration
Bio3 Research Granted by the Australian PO a Patent in the Field of HMGB1

 

PRZOOM - /newswire/ - Milano, Italy, 2007/03/15 - Italy, has been granted by the Australian Patent Office a patent in the field of cardiovascular diseases related to HMGB1 over-expression and for the use of HMGB1 protein in connective tissue regeneration.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bio3 Research S.r.l. announced today that the Australian Patent Office has granted the company the patent in the HMGB1 (High Mobility Group Box 1 protein) field which entitles the use of antagonist molecules (Mabs and their fragments, Small Molecules inhibitors and antagonist molecules having sequence homology with HMG Box) that can bind the functional HMG Box binding domain of the receptor RAGE for the preparation of therapeutic agents for the treatment of vascular diseases, such as Atherosclerosis and Restenosis.
Furthermore, the granted patent entitles Bio3 Research to utilize HMGB1 as such and its fragments for the preparation of therapeutic agents which facilitate and/or induce Connective Tissue Regeneration.

Mr. Francesco Paolo Pilato, CEO Bio3 Research S.r.l., said: “We are very pleased for the Australian PO decision to grant the company said patent, which comes on the top of the already granted patent in Italy. Said patent entitles the company or licensed third parties the use of HMGB1 antagonists to treat cardiovascular disorders and to develop drugs based on HMGB1 as such and its fragments in the regeneration of damaged tissues. Remarkable scientific contribution has come from the studies conducted by Prof. Marco E. Bianchi (Inventor) an Associate Scientist of Bio3 Research. We strongly believe that the Pharmaceutical environment will soon consider HMGB1 as an innovative biological target for the development of drugs to prevent atherosclerotic plaque progression and restenosis after angioplasty. We are also very keen to develop treatments based on the use of HMGB1 as such, to regenerate damaged connective tissues. Preliminary animal data in cartilage repair are encouraging Bio3 Research to proceed further, and extend researches to bone matrix reconstitution and wound healing. We anticipate with much pleasure that soon patents will be also granted in other countries.”

About Bio3 Research S.r.l.

Bio3 Research S.r.l. (bio3research.com), an Italian company founded in 2001, has headquarters in Milan and an office at the Bioindustry Park of Canavese (Turin). Bio3 Research works with research institutions, individual scientists and early-stage companies to identify, protect and exploit commercially promising intellectual property in the life sciences. Such assistance may include pre-clinical development and negotiation of strategic industrial partnerships. Bio3 Research’s activity focuses mainly on the field of HMBG1-related cardiovascular disorders and use of HMGB1 and its fragments in connective tissue regeneration. Other fields of interest include skin and renal diseases.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Bio3 Research Srl

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bio3 Research Granted by the Australian PO a Patent in the Field of HMGB1

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Federico Gardini - Bio3Research.com 
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bio3 Research Srl securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Bio3 Research Srl / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today